Clinical Trial Search

Primary: Combined Clinically Significant Postoperative Pancreatic Fistula and Intra-abdominal Abscess — 8 Participants

Primary: Factor IX Activity Levels — 30.6 Factor IX activity (%)

Primary: Number of Participants Experiencing Adverse Events — 5; 4; 13; 10 Participants

Primary: Prostate-specific Antigen (PSA) Response — 48; 48 percentage of participants — p=.6789

Primary: Grade II-IV Acute GVHD — 30 percentage of participants

Primary: Number of Participants With Adverse Events for TERN-101 Versus Placebo — 10; 13; 14; 15 Participants

Primary: Rate of 6 Month Progression-Free Survival — 18; 15; 4; 12 Participants

Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants

Primary: Plasticity Improvement (Change in Tone Matching Threshold) — 13.9; 5.3; 11; -0.05 log ratio

Primary: Percentage of Participants Who Have a Defined Increase in 24-hour Urine Volume From Baseline to Week 5 — 33 percentage of participants

Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) as a Measure of Safety Profile to Determine Recommended Dose of Ponatinib — 0; 0; 1; 1 Participants

Primary: Progression-free Survival — 5.98; 7.03; 9.20 months

Primary: Response Rate (Complete Response or Partial Response) — 1; 1; 2; 12 Participants

Primary: Area Under the Curve (AUC) of Shedding of SARS-CoV-2 Virus — 95.3; 93 cycles*days — p=0.89

Primary: Number of Participants With Treatment Success — 23 Participants